Q
Qiao-Xin Li
Researcher at Florey Institute of Neuroscience and Mental Health
Publications - 169
Citations - 12411
Qiao-Xin Li is an academic researcher from Florey Institute of Neuroscience and Mental Health. The author has contributed to research in topics: Amyloid precursor protein & P3 peptide. The author has an hindex of 58, co-authored 149 publications receiving 10805 citations. Previous affiliations of Qiao-Xin Li include Menzies Research Institute & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
Akinori Nakamura,Naoki Kaneko,Victor L. Villemagne,Takashi Kato,James D. Doecke,Vincent Dore,Christopher Fowler,Qiao-Xin Li,Ralph N. Martins,Christopher C. Rowe,Taisuke Tomita,Katsumi Matsuzaki,Kenji Ishii,Kazunari Ishii,Yutaka Arahata,Shinichi Iwamoto,Kengo Ito,Koichi Tanaka,Colin L. Masters,Katsuhiko Yanagisawa +19 more
TL;DR: The measurement of high-performance plasma amyloid-β biomarkers by immunoprecipitation coupled with mass spectrometry demonstrates the potential clinical utility of plasma biomarkers in predicting brain amyloids-β burden at an individual level and shows cost–benefit and scalability advantages over current techniques.
Journal ArticleDOI
Metal-Protein Attenuation With Iodochlorhydroxyquin (Clioquinol) Targeting Aβ Amyloid Deposition and Toxicity in Alzheimer Disease: A Pilot Phase 2 Clinical Trial
Craig W. Ritchie,Ashley I. Bush,Andrew Mackinnon,Steve Macfarlane,Maree Mastwyk,Lachlan MacGregor,Lyn Kiers,Robert A. Cherny,Qiao-Xin Li,Amanda Tammer,Darryl Carrington,Christine Mavros,Irene Volitakis,Michel Xilinas,David Ames,Stephen M. Davis,Konrad Beyreuther,Rudolph E. Tanzi,Colin L. Masters +18 more
TL;DR: This pilot phase 2 study supports further investigation of this novel treatment strategy using a metal-protein-attenuating compound, and the effect of treatment was significant in the more severely affected group.
Journal ArticleDOI
Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ
Paul A. Adlard,Robert A. Cherny,Robert A. Cherny,David Finkelstein,David Finkelstein,Elisabeth Gautier,Elysia Robb,Mikhalina Cortes,Irene Volitakis,Xiang Liu,Jeffrey P. Smith,Keyla Perez,Keyla Perez,Katrina M. Laughton,Katrina M. Laughton,Qiao-Xin Li,Qiao-Xin Li,Susan A. Charman,Joseph A. Nicolazzo,Simon Wilkins,Simon Wilkins,Karolina Deleva,Toni Lynch,Gaik Beng Kok,Craig W. Ritchie,Rudolph E. Tanzi,Roberto Cappai,Roberto Cappai,Colin L. Masters,Colin L. Masters,Kevin J. Barnham,Kevin J. Barnham,Ashley I. Bush,Ashley I. Bush +33 more
TL;DR: The current data demonstrate that ionophore activity, inhibition of in vitro metal-mediated Abeta reactions, and blood-brain barrier permeability are indices that predict a potential disease-modifying drug for AD.
Journal ArticleDOI
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Niklas Mattsson,Ulf Andreasson,Staffan Persson,Hiroyuki Arai,Sat Dev Batish,Sergio Bernardini,Luisella Bocchio-Chiavetto,Marinus A. Blankenstein,Maria Berrocal Carrillo,Sonia Chalbot,Els Coart,Davide Chiasserini,Neal Cutler,Gunilla Dahlfors,Stefan Duller,Anne M. Fagan,Orestes Vicente Forlenza,Giovanni B. Frisoni,Douglas Galasko,Daniela Galimberti,Harald Hampel,Aase Handberg,Michael T. Heneka,Adrianna Z. Herskovits,Sanna-Kaisa Herukka,David M. Holtzman,Christian Humpel,Bradley T. Hyman,Khalid Iqbal,Mathias Jucker,Stephan A. Kaeser,Elmar Kaiser,Elisabeth Kapaki,Daniel Kidd,Péter Klivényi,Cindy Soendersoe Knudsen,Markus P. Kummer,James Lui,Albert Lladó,Piotr Lewczuk,Qiao-Xin Li,Ralph N. Martins,Colin L. Masters,John McAuliffe,Marc Mercken,Abhay Moghekar,José Luis Molinuevo,Thomas J. Montine,William Nowatzke,Richard O'Brien,Markus Otto,George P. Paraskevas,Lucilla Parnetti,Ronald C. Petersen,David Prvulovic,Herman P M de Reus,Robert A. Rissman,Elio Scarpini,Alessandro Stefani,Hilkka Soininen,Johannes Schröder,Leslie M. Shaw,Anders Skinningsrud,Brith Skrogstad,Annette Spreer,Leda Leme Talib,Charlotte E. Teunissen,John Q. Trojanowski,Hayrettin Tumani,Robert M. Umek,Bianca Van Broeck,Hugo Vanderstichele,László Vécsei,Marcel M. Verbeek,Manfred Windisch,Jing Zhang,Henrik Zetterberg,Kaj Blennow +77 more
TL;DR: The cerebrospinal fluid biomarkers amyloid β (Aβ)‐42, total‐Tau (T‐tau), and phosphorylated‐t Tau (P‐tAU) demonstrate good diagnostic accuracy for Alzheimer's disease (AD), but there are large variations in biomarker measurements between studies, and between and within laboratories.
Journal ArticleDOI
Overexpression of Alzheimer's Disease Amyloid-β Opposes the Age-dependent Elevations of Brain Copper and Iron
Christa J. Maynard,Roberto Cappai,Roberto Cappai,Irene Volitakis,Robert A. Cherny,Robert A. Cherny,Anthony R. White,Anthony R. White,Konrad Beyreuther,Colin L. Masters,Colin L. Masters,Ashley I. Bush,Ashley I. Bush,Ashley I. Bush,Qiao-Xin Li,Qiao-Xin Li +15 more
TL;DR: It is demonstrated that overexpression of the carboxyl-terminal fragment of APP, containing Aβ, results in significantly reduced copper and iron levels in transgenic mouse brain, while overexposure of the APP in Tg2576 transgenic mice results inificantly reduced copper, but not iron, levels prior to the appearance of amyloid neuropathology and throughout the lifespan of the mouse.